Dyne Therapeutics (DYN) Income from Continuing Operations (2019 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Income from Continuing Operations of 116519000.0 in Q1 2026, down 7.42% quarter-over-quarter from 108472000.0 in Q4 2025, and down 1.08% on a YoY basis from 117793274.88 in Q1 2025.
Dyne Therapeutics (DYN) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Dyne Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 116519000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 1.08% year-over-year to 116519000.0; the TTM figure through Mar 2026 stood at 442571000.0 (down 20.92% YoY), while the FY2025 annual figure was 438325000.0, down 38.29% from the prior year.
- Income from Continuing Operations was 116519000.0 for Q1 2026 at Dyne Therapeutics, down from 108472000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 35553000.0 in Q1 2022 to a low of 116519000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 75134352.94 across 5 years, with a median of 65937000.0 in 2023.
- Biggest YoY gain for Income from Continuing Operations was 25.06% in 2022; the steepest drop was 74.64% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 38803000.0 in 2022, then slumped by 69.93% to 65937000.0 in 2023, then plunged by 35.76% to 89516000.0 in 2024, then retreated by 21.18% to 108472000.0 in 2025, then dropped by 7.42% to 116519000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 116519000.0 (Q1 2026), 108472000.0 (Q4 2025), and 108320000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | -116.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -116.52 Mn |
| Dec 31, 2025 | -108.47 Mn |
| Sep 30, 2025 | -108.32 Mn |
| Jun 30, 2025 | -109.26 Mn |
| Mar 31, 2025 | -115.27 Mn |
| Dec 31, 2024 | -89.52 Mn |
| Sep 30, 2024 | -96.29 Mn |
| Jun 30, 2024 | -64.91 Mn |
| Mar 31, 2024 | -66.16 Mn |
| Dec 31, 2023 | -65.94 Mn |
| Sep 30, 2023 | -60.08 Mn |
| Jun 30, 2023 | -64.53 Mn |
| Mar 31, 2023 | -43.97 Mn |
| Dec 31, 2022 | -38.80 Mn |
| Sep 30, 2022 | -41.38 Mn |
| Jun 30, 2022 | -52.31 Mn |
| Mar 31, 2022 | -35.55 Mn |
| Dec 31, 2021 | -51.78 Mn |
| Sep 30, 2021 | -42.58 Mn |
| Jun 30, 2021 | -29.96 Mn |